Clinical Use of PARP Inhibitors in BRCA Mutant and Non-BRCA Mutant Breast Cancer [0.03%]
用于BRCA突变型和非BRCA突变型乳腺癌患者的PARP抑制剂临床应用
Filipa Lynce,Mark Robson
Filipa Lynce
The use of poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of patients with germline BRCA mutations (gBRCAm) and breast cancer, both in the early and advanced settings, is a success of genomically-directed treatment. These a...
Clinical Application of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Ovarian Cancer [0.03%]
卵巢癌中聚(腺苷二磷酸核糖)聚合酶(PARP)抑制剂的临床应用
Melissa M Pham,Monica Avila,Emily Hinchcliff et al.
Melissa M Pham et al.
The treatment of ovarian cancer has remained a clinical challenge despite high rates of initial response to platinum-based chemotherapy. Patients are generally diagnosed at an advanced stage with significant disease burden, which portends t...
Development of Homologous Recombination Functional Assays for Targeting the DDR [0.03%]
同源重组功能测定法靶向DDR的发展研究
Ailsa J Oswald,Charlie Gourley
Ailsa J Oswald
Identification of tumours that have homologous recombination deficiency (HRD) has become of increasing interest following the licensing of PARP inhibitors. Potential methods to assess HRD status include; clinical selection for platinum sens...
Mark J O&#x;Connor,Josep V Forment
Mark J O&#x;Connor
Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) represent the first medicines based on the targeting of the DNA damage response (DDR). PARPi have become standard of care for first-line maintenance treatment in ovarian cancer and have ...
Exploiting Cancer Synthetic Lethality in Cancer-Lessons Learnt from PARP Inhibitors [0.03%]
利用癌症合成致死性——来自PARP抑制剂的启示
Stephen J Pettitt,Colm J Ryan,Christopher J Lord
Stephen J Pettitt
PARP inhibitors now have proven utility in the treatment of homologous recombination (HR) defective cancers. These drugs, and the synthetic lethality effect they exploit, have not only taught us how to approach the treatment of HR defective...
Ruth Plummer
Ruth Plummer
PARP inhibitors first entered the clinic in 2003 in combination with DNA damaging agents in an attempt to overcome treatment resistance to established agents. A brief overview of ADP-ribosylator enzyme biology and the early preclinical deve...
Medical Aid in Dying [0.03%]
辅助自杀医疗救助法案
Kim Callinan,David Grube,Victoria Ramirez
Kim Callinan
As the nation's 75 million baby boomers enter into a new phase of their life, care for their aging parents, and contemplate their own mortality, many have come to realize that our end-of-life care system is hamstrung by outdated modes of dy...
Eric D Mecusker
Eric D Mecusker
The human desire to explore our world has led to dramatic shifts in science, technology, and culture. As our knowledge expands so too has our ability to more definitively reach places once thought inhospitable or beyond our grasp. In the ea...
Sarah Janelle Hernandez
Sarah Janelle Hernandez
An exploration of the Natural Death Care Movement's economic and eco-friendly mediums of green burial and how the movement is revolutionizing an ecological, sociocultural, and spiritual connection in our inevitable passage toward organic de...
The Living Wake [0.03%]
活人葬礼
Stefanie N Mooney
Stefanie N Mooney
The Living Funeral is a unique way to celebrate the life of someone while it is still being lived. Cultural, familial, religious, and culinary traditions are all ways to make the event meaningful for family and friends in the presence of th...